Self-Injections Market: Evolving Technology In Pharmaceutical Industry Trends Analysis 2018 - Dominated By Janssen Biotech, Inc, Haselmeier AG, 3M, AbbVie Inc, Antares Pharma, BD, Baxter, Penjet Corporation, PharmaJet, Gerresheimer AG - Forecast 2025

Self-Injections Market Research Report provides in-depth information and professional study 2018-2025 of Self-Injections Industry. This Report is segmented into Manufactures, Types, Applications and Regions. Self-Injections Market report also shares details of upstream raw materials, downstream demand, and production value with some important factor that can lead to market growth.

Increasing development of biologic drugs for the treatment of autoimmune diseases, chronic diseases, which include heart disease, diabetes, stroke, and chronic respiratory problems, are expected to fuel the growth of the global self-injection market. It is estimated to grow in the forecast period of 2018 to 2025 with the CAGR of 22.5%.

Get Free Sample of Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-self-injections-market

According to Data Bridge Market Research new Market report, “Global Self-Injections Market By Product Type (Devices{ Needle-Free Injectors [By Product Type {Fillable, Prefilled}, By Technology {Jet-Based, Spring-Based, Laser-Powered, Vibration-Based}, By Usability {Reusable, Disposable}], Auto Injectors [By Product {Fillable, Prefilled}, By Technology {Automated, Manual}, By Design {Standardized, Customized}, By Usability {Reusable, Disposable}], Pen Injectors[ By Product {Single-Chambered, Dual-chambered}, By Design {Standard, Customized}, By Usability {Reusable, Disposable}, Wearable Injectors, Other Devices}, Formulations {Conventional Drug Delivery Formulations [Solutions, Reconstituted/Lyophilized Formulations, Suspensions, Emulsions], Novel Drug Delivery Formulations [Colloidal Dispersions {Liposomes, Niosomes, Polymeric/Mixed Micelles, Nano Particles {Nano suspensions, Nano emulsions/Micro emulsions, Solid-Lipid Nanoparticles}, Micro particles], Long-Acting Formulations}), By Therapeutic Application {Auto immune diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therapy, Others}, By Dosage Form {Single Dose, Multi-Dose}, By Route of Administration {Skin, Circulatory /Musculoskeletal, Organs, Central Nervous System}, By End-User {Patient, Physicians, Home Care Settings, Others}, By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast is projected to reach USD 145.35 billion by 2025, at a CAGR of 22.5% during the forecast period of 2018 to 2025.

Global Self-Injections Market

Self –injections are the method of drug administration at home. Patients who are suffering from diabetes and insulin dependent, self-injection medication are an excellent method. Patients suffering from arthritis also use self-injection medication as this is easy and reliable method. The demand for self-injection is rising due to rise in auto-immune diseases. According to world health organization, there is over 5% of the global population suffering from autoimmune disease. Various companies have launched products for the self-injection market. For instance, in September 2015 Pfizer, launched injectable contraceptive, SayanaPress (medroxyprogesterone acetate), for women in the United Kingdom for administration by self-injection. This self-injection contraceptive is approved from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Furthermore, Elcam Medical’s product The Flexi-Q HV, which is a fully disposable auto-injector designed for low to high viscosity liquid drugs in prefilled syringes. This single-use auto-injector features passive needle shielding, allows better patient safety and encourages patient compliance in self-injection. In July 2017, GlaxoSmithKline plc, got approval from the U.S. food and drug administration (FDA) for subcutaneous formulation of Benlysta (belimumab), which is used for the treatment of systemic lupus erythematosus in adult patients. Systemic Lupus Erythematosus (SLE) is the most common form of lupus, a chronic, incurable autoimmune disease producing autoantibodies that can attack almost any system in the body.

A research conducted by Massachusetts institute of technology revealed that the scientists are trying to develop needle-less injection technology that could see doctors administering drugs using a tiny high-pressured jet in future. This is expected to eliminate the use of needles by delivering the drug into tissues using high pressure steam. These technological advancements by key players are supporting the growth of the market.

Table Of Contents Available For This Market, Request For TOC Here @ https://databridgemarketresearch.com/toc/?dbmr=global-self-injections-market

Global Self-Injections Market– Market Segmentation:

The global market for self-injection by the following sub-categories is presented

 By Product Type

• Devices

o Needle-Free Injectors

 By Product Type
 Fillable
 Prefilled
 By Technology
 Jet-Based
 Spring-Based
 Laser-Powered
 Vibration-Based
 By Usability
 Reusable
 Disposable

o Auto Injectors

 By Product

 Fillable
 Prefilled

 By Technology

 Automated
 Manual
 By Design
 Standardized
 Customized
 By Usability
 Reusable
 Disposable

o Pen Injectors

 By Product

 Single-Chambered
 Dual-chambered
 By Design
 Standard
 Customized

 By Usability

 Reusable
 Disposable

o Wearable Injectors

o Other Devices

• Formulations

o Conventional Drug Delivery Formulations

 Solutions
 Reconstituted/Lyophilized Formulations
 Suspensions
 Emulsions

o Novel Drug Delivery Formulations

 Colloidal Dispersions
 Liposomes
 Niosomes
 Polymeric/Mixed Micelles
 Nano Particles
 Nano suspensions
 Nano emulsions/Micro emulsions
 Solid-Lipid Nanoparticles
 Micro particles

o Long-Acting Formulations

 By Therapeutic Application

• Auto immune diseases
• Hormonal Disorders
• Oncology
• Orphan Diseases
• Pain Management
• Respiratory Therapy
• Others

 By Dosage Form

• Single Dose
• Multi-Dose

 By Route of Administration

• Skin
• Circulatory /Musculoskeletal
• Organs
• Central Nervous System

 By End-User

• Patient
• Physicians
• Home Care Settings
• Others

 By Geography

• North America
• South America
• Europe
• Asia-Pacific
• Middle East and Africa

Questions? We’ll Put You on the Right Path Request Analyst Call @ https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-self-injections-market

FACTORS DRIVING GROWTH IN THE GLOBAL SELF-INJECTIONS MARKET

Increasing incidence of auto-immune and chronic disease:

Patients suffering from diabetes and patients suffering from arthritis mostly prefer self-injection.

According to arthritis foundation, arthritis is the leading cause of disability among adults in the U.S. about 54 million adults have doctor-diagnosed arthritis. Almost 300,000 babies and children have arthritis or a rheumatic condition. The most common type of arthritis is osteoarthritis, which affects an estimated 31 million Americans. It is expected that about 78 million people will suffer from arthritis by 2040.

According to world health organization, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. In 2015, an estimated 1.6 million deaths were directly caused by diabetes. Another 2.2 million deaths were attributable to high blood glucose in 2012. WHO projects that diabetes will be the seventh leading cause of death in 2030.

With increasing prevalence of diabetes and arthritis among people is increasing demand for self-injection, which is expected make a boom in future.

Viscosity of biologic drugs the auto-injector is expected to serve as one of the best ways of drug delivery by self-injections:

Biologic drugs are mostly used in arthritis. methotrexate which is an anti-rheumatic drug has been used for several years. But inventions of various self-administered biologic drugs such as TNF-blockers Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), and Cimzia (certolizumab pegol)is providing new ways in drug administration. Kineret (anakinra), a biologic drug that inhibits the action of interleukin, is administered subcutaneously.

SIMPONI is the first and self-injectable biologic treatment with just one injection each month for adults with moderate to severe rheumatoid arthritis, with the medicine methotrexate and also used in active ankylosing spondylitis.

With the increasing incidences of arthritis and new inventions and technological advancements in biologic drugs, this market is expected to have a stable growth in future.

Top Key Players:

Some of the major market players in this market are Janssen Biotech, Inc, Haselmeier AG, 3M, AbbVie Inc, Antares Pharma, BD, Baxter, Penjet Corporation, PharmaJet, Gerresheimer AG, Pfizer Inc, TERUMO CORPORATION, Mylan N.V., SHL Group, Bespak, Insulet corporation, Unilife Corp , West Pharmaceutical Services, Inc, Ypsomed, Eli Lilly and Company, Alkermes, AptarGroup, Inc, Credence MedSystems, Inc, Owen Mumford. among others.

Customization With Discount Available On This Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-self-injections-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.